| Characteristics (mean ± SD) |
RA patients (40) |
Control (30) |
p value |
| Age (years) |
46.95 ± 11.60 |
43.7 ± 9.9 |
0.542 |
| Sex (F/M) |
26/14 |
18/12 |
0.532 |
| Disease duration (years) |
4.57 ± 2.59 |
- |
|
| Morning stiffness (min) |
18.84 ± 9.04 |
- |
|
| VAS (0–10) |
4.62 ± 1.40 |
- |
|
| Number of swollen joints |
2.32 ± 1.18 |
- |
|
| Number of tender joints |
3.89 ± 2.08 |
- |
|
| DAS28 score |
3.79 ± 0.66 |
- |
|
| HAQ score |
11.49 ± 4.15 |
- |
|
| ESR (mm/1st hr) |
42.65 ± 8.59 |
- |
|
| Rheumatoid factor (%) |
46.0 ± 9.8 |
- |
|
| CRP (mg/l) |
18.65 ± 9.59 |
- |
|
| Body mass index (BMI) |
14.15 ± 11.48 |
27.85 ± 2.62 |
|
| Anti-CCP2 (U/ml) |
89.2 ± 11.3 |
14.8±3.21 |
<0.001** |
| Anti-MCV (U/ml) |
114.45 ± 16.57 |
9.05 ± 3.67 |
<0.001** |
RF: Rheumatoid Factor; MS: Morning Stiffness; VAS: Visual Analog Scale of
pain; DAS28: Disease activity for 28 joint indices score; HAQ: Health Assessment
Questionnaire; ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein;
BMI: Body Mass Index; Anti-CCP2: Antibodies against Cyclic Citrullinated
Peptide2; Anti-MCV: Antibodies against Mutated Citrullinated Vimentin
** Highly significant |
